KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Minority Interest: 2017-2024

Historic Minority Interest for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Dec 2024 value amounting to $65.0 million.

  • Amneal Pharmaceuticals' Minority Interest rose 13.18% to $67.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.8 million, marking a year-over-year increase of 13.18%. This contributed to the annual value of $65.0 million for FY2024, which is 57.35% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Minority Interest is $65.0 million, which was up 57.35% from $41.3 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Minority Interest high stood at $65.0 million for FY2024, and its period low was $11.8 million during FY2020.
  • Its 3-year average for Minority Interest is $43.7 million, with a median of $41.3 million in 2023.
  • Data for Amneal Pharmaceuticals' Minority Interest shows a peak YoY surged of 65.51% (in 2023) over the last 5 years.
  • Amneal Pharmaceuticals' Minority Interest (Yearly) stood at $11.8 million in 2020, then spiked by 43.23% to $16.9 million in 2021, then surged by 47.57% to $24.9 million in 2022, then skyrocketed by 65.51% to $41.3 million in 2023, then soared by 57.35% to $65.0 million in 2024.